wiki pageCreated: 2026-04-02T07:19:14By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-proteins-insr-protein
📖 Wiki Page
protein631 wordssynced 2026-04-02
Insulin Receptor (INSR) Protein
Overview
The Insulin Receptor (INSR) is a transmembrane tyrosine kinase receptor encoded by the INSR gene located on chromosome 19q13.2. This receptor belongs to the family of insulin receptor substrate receptors and functions as a critical mediator of metabolic and neurotrophic signaling. While classically recognized for its role in glucose homeostasis and metabolic regulation throughout the body, the INSR has emerged as an important factor in neuronal survival, synaptic plasticity, and neurodegeneration. The insulin receptor exists in two isoforms—INSR-A and INSR-B—generated through alternative splicing, with INSR-A predominantly expressed in neural tissues and associated with enhanced mitogenic signaling, while INSR-B is more prevalent in peripheral metabolic tissues.
Function/Biology
The INSR is a heterotetrameric protein consisting of two extracellular α-subunits and two transmembrane β-subunits linked by disulfide bonds. Upon insulin binding, the receptor undergoes autophosphorylation at critical tyrosine residues within its intracellular kinase domain, initiating a cascade of phosphorylation events. This activation recruits and phosphorylates insulin receptor substrates (IRS-1, IRS-2, IRS-3, and IRS-4), which serve as docking sites for proteins containing SH2 domains. The primary intracellular signaling pathways activated by INSR include the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway.
...
Insulin Receptor (INSR) Protein
Overview
The Insulin Receptor (INSR) is a transmembrane tyrosine kinase receptor encoded by the INSR gene located on chromosome 19q13.2. This receptor belongs to the family of insulin receptor substrate receptors and functions as a critical mediator of metabolic and neurotrophic signaling. While classically recognized for its role in glucose homeostasis and metabolic regulation throughout the body, the INSR has emerged as an important factor in neuronal survival, synaptic plasticity, and neurodegeneration. The insulin receptor exists in two isoforms—INSR-A and INSR-B—generated through alternative splicing, with INSR-A predominantly expressed in neural tissues and associated with enhanced mitogenic signaling, while INSR-B is more prevalent in peripheral metabolic tissues.
Function/Biology
The INSR is a heterotetrameric protein consisting of two extracellular α-subunits and two transmembrane β-subunits linked by disulfide bonds. Upon insulin binding, the receptor undergoes autophosphorylation at critical tyrosine residues within its intracellular kinase domain, initiating a cascade of phosphorylation events. This activation recruits and phosphorylates insulin receptor substrates (IRS-1, IRS-2, IRS-3, and IRS-4), which serve as docking sites for proteins containing SH2 domains. The primary intracellular signaling pathways activated by INSR include the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway.
In the nervous system, INSR signaling promotes neuronal survival through Akt-mediated phosphorylation and inactivation of pro-apoptotic proteins such as forkhead box O (FOXO) and glycogen synthase kinase-3 (GSK-3β). Beyond metabolic functions, the INSR regulates dendritic spine density, synaptic transmission, and long-term potentiation—processes fundamental to learning and memory. The receptor also influences mitochondrial function and cellular energy metabolism, critical for neurons with high metabolic demands.
Role in Neurodegeneration
Emerging evidence implicates insulin signaling deficiency and INSR dysfunction in multiple neurodegenerative diseases. Reduced insulin signaling has been documented in Alzheimer's disease brains, with some researchers proposing Alzheimer's as "type 3 diabetes." In Alzheimer's pathology, impaired INSR signaling reduces Akt activation, leading to increased phosphorylation of tau protein and reduced clearance of amyloid-beta. The PI3K/Akt pathway activation normally promotes clearance of amyloid-beta through both autophagy and non-amyloidogenic processing of amyloid precursor protein; dysfunction in this pathway accelerates accumulation of pathological proteins.
In Parkinson's disease, INSR signaling deficiency has been associated with increased vulnerability of dopaminergic neurons to oxidative stress and alpha-synuclein-induced toxicity. Reduced INSR-mediated Akt signaling impairs mitochondrial biogenesis and antioxidant defense mechanisms. Similarly, in Huntington's disease, insulin signaling dysfunction contributes to energy metabolism abnormalities and increased susceptibility to mutant huntingtin toxicity. In amyotrophic lateral sclerosis (ALS), altered INSR expression and signaling have been observed in motor neurons and muscle tissue, potentially contributing to neuromuscular junction degeneration and motor neuron loss.
Molecular Mechanisms
INSR dysfunction in neurodegeneration operates through several interconnected mechanisms. Impaired insulin signaling reduces Akt-mediated phosphorylation of GSK-3β, leading to its hyperactivity and excessive tau phosphorylation in Alzheimer's disease. Diminished PI3K activation compromises autophagy-mediated clearance of aggregated proteins. Additionally, reduced INSR signaling attenuates the activation of mammalian target of rapamycin complex 1 (mTORC1), affecting protein synthesis and synaptic plasticity. INSR dysfunction also impairs mitochondrial function through reduced peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) expression, decreasing oxidative phosphorylation capacity and increasing reactive oxygen species production.
Clinical/Research Significance
INSR represents a potential therapeutic target in neurodegenerative disease treatment. Insulin sensitizers and compounds enhancing INSR signaling show neuroprotective effects in preclinical models. The discovery of reduced INSR signaling in neurodegenerative brains has prompted investigation of insulin-based therapies, including intranasal insulin administration to bypass the blood-brain barrier. Understanding INSR biology may elucidate the connection between metabolic dysfunction and neurodegeneration, offering new preventive and therapeutic strategies.